Additional file 4: of DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines

Retreatment of the pooled surviving U-1810-clones from a first round of clonogenic survival, where the first treatment is indicated for cisplatin-surviving (10 μM, Cisplatin as 1st) or untreated (Untreated as 1st) clones. (A) The relative clonogenic survival in the first (1st) round is depicted in the first white bar, the grey bars are data from the retreated (2nd) experiment as described above, also using 10 μM cisplatin. (B) MTT cell viability data. Doses used for the retreatment were from 0.5-50 μM cisplatin and viability was analyzed after 72 h. Average ± SD from three experiments, MTT was performed in triplicate. (TIFF 54 kb